# ATXN3 WILDTYPE Research Report **Protein:** ATXN3 WILDTYPE **Variant:** Q27 **UniProt ID:** P54252 **Disease Association:** Spinocerebellar ataxia type 3 (Machado-Joseph) **Report Generated:** 2026-07-14 01:55 UTC **AlphaFold Confidence (pLDDT):** 71.9% **Structure Folded:** 2026-06-23 --- ## Structure Summary Spinocerebellar ataxia type 3 (also called Machado-Joseph disease) is caused by an abnormal expansion of CAG repeats in the ATXN3 gene, which produces a protein with too many glutamine amino acids that forms toxic clumps in brain cells. This structural prediction of the normal ATXN3 protein with 27 glutamines (Q27) achieved moderate confidence (average score 71.9 out of 100), revealing both well-defined functional regions and flexible domains that may be critical for understanding how the expanded versions cause disease. While the moderate confidence limits definitive structural conclusions, this model provides a foundation for comparing how disease-causing expansions might alter protein behavior and aggregation patterns. --- ATXN3 is a deubiquitinating enzyme that removes ubiquitin tags from proteins, playing important roles in protein quality control and cellular stress responses. The protein contains specialized ubiquitin-interacting motifs (UIMs) that allow it to recognize and process ubiquitin-tagged substrates [1][3]. In spinocerebellar ataxia type 3, the most common inherited ataxia worldwide, expansions beyond 52-86 CAG repeats in the ATXN3 gene produce mutant proteins with abnormally long polyglutamine tracts that aggregate into toxic inclusions in neurons [2][6]. Understanding the normal protein structure is essential for determining how these expansions trigger the disease process. The AlphaFold2 structural prediction of wildtype ATXN3 with 27 glutamines achieved an average confidence score of 71.9, indicating moderate overall reliability with likely variation across different protein regions. This confidence level suggests that while some domains are well-predicted, others remain uncertain and require cautious interpretation. The moderate confidence is expected for ATXN3 because it contains both structured catalytic domains and intrinsically flexible regions that naturally lack fixed three-dimensional shapes. These flexible regions, particularly those containing the polyglutamine tract and UIMs, are thought to play critical roles in protein-protein interactions and phase separation behavior [3]. Recent research has revealed that ATXN3 can undergo liquid-liquid phase separation (LLPS), a process where proteins spontaneously separate into droplet-like condensates within cells, and that this property is influenced by the polyglutamine length and the number of UIMs [3]. The transition from liquid droplets to solid aggregates appears central to disease pathogenesis, with mutant ATXN3 showing accelerated conversion to irreversible amyloid-like structures [3]. Given the moderate confidence of this structural prediction, direct comparisons with these biophysical findings would require experimental validation, but the model may help identify which regions undergo conformational changes during aggregation. The clinical relevance of understanding ATXN3 structure extends beyond basic research, as genome editing approaches targeting the ATXN3 gene have shown promise in improving cellular abnormalities associated with SCA3, including restoration of normal Golgi apparatus structure [5]. Longitudinal studies of SCA3 patients have identified biological markers that change over time, providing targets for therapeutic intervention [6]. Additionally, genetic modifiers such as intermediate-length CAG repeats in the ATXN2 gene can influence SCA3 disease progression, highlighting the complex genetic architecture underlying clinical outcomes [4]. While this structural model of the normal Q27 protein has limitations due to moderate confidence, it provides a baseline for understanding how pathogenic expansions disrupt protein folding, cellular localization, and interactions with quality control machinery like CHIP-mediated stress responses [1]. ## Works Cited [1] Tang et al. (2026). Single-Cell RNA Sequencing Reveals Impaired CHIP-Mediated Heat Stress Response in SCA3 Pathogenesis. Molecular neurobiology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41701293/) [2] Wang et al. (2025). Familial spinocerebellar ataxia type 3: A case report of multi-generational presentation. Medicine. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40797466/) [3] Prasad et al. (2025). Rad23B Delays Ataxin-3 Liquid-to-solid Phase Transition Through Heterotypic Buffering. Journal of molecular biology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40684934/) [4] Lauerer et al. (2025). Influence of ATXN2 intermediate CAG repeats, 9bp duplication and alternative splicing on SCA3 pathogenesis. Acta neuropathologica communications. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40684213/) [5] Wang et al. (2025). Genome editing in spinocerebellar ataxia type 3 cells improves Golgi apparatus structure. Scientific reports. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40204795/) [6] Berger et al. (2025). Progression of biological markers in spinocerebellar ataxia type 3: longitudinal analysis of prospective data from the ESMI cohort. The Lancet regional health. Europe. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40678042/) ## Similar Research **Integrative genetic analysis illuminates ALS heritability and identifies risk genes.** Megat et al. (2023) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/36670122/) **Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno-Sandwich Assay.** Ashton et al. (2025) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40401628/) **Frontotemporal dementia. How to deal with its diagnostic complexity?** Antonioni et al. (2025) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/39911129/) **Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes.** Sogorb-Esteve et al. (2025) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/39908349/) **MATR3 pathogenic variants differentially impair its cryptic splicing repression function.** Khan et al. (2024) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/38320753/) --- ## Open Targets Disease Associations | Disease | Score | Data Sources | |---------|-------|--------------| | Machado-Joseph disease | 0.568 | literature, animal_model, genetic_association, genetic_literature | | Spinocerebellar ataxia type 3 | 0.493 | literature, animal_model, genetic_association | | Abnormality of the skeletal system | 0.400 | genetic_association | | Machado-Joseph disease type 1 | 0.377 | animal_model, genetic_association | | Machado-Joseph disease type 2 | 0.377 | animal_model, genetic_association | | Machado-Joseph disease type 3 | 0.370 | genetic_association | | Parkinson disease | 0.204 | literature, animal_model, genetic_association | | late-onset Parkinson disease | 0.196 | animal_model, genetic_association | | Hereditary late-onset Parkinson disease | 0.193 | animal_model, genetic_association | | hereditary disease | 0.193 | literature, genetic_association | *...and 865 more associations* --- ## AI Research Brief # Research Brief: ATXN3 Wildtype Q27 ## Pathogenic Mechanisms ATXN3 encodes ataxin-3, a deubiquitinase enzyme with critical roles in protein quality control, functioning through its cysteine-type deubiquitinase activity and interactions with key cellular partners including VCP, BECN1, and caspases. The wildtype Q27 variant contains 27 CAG repeats encoding a polyglutamine tract, well below the pathogenic threshold of ≥60 repeats associated with spinocerebellar ataxia type 3 (SCA3/Machado-Joseph disease). Recent research has elucidated normal ataxin-3 behavior including phase separation properties and stress response mechanisms that become dysregulated in expanded forms. The protein participates in actin cytoskeleton organization and cellular responses to amino acid starvation and heat stress, functions that are preserved in the wildtype variant. Structural analyses reveal an aggregation-prone region at residues 148-152 (score: 0.56), suggesting that even wildtype ataxin-3 possesses inherent aggregation propensity that is dramatically exacerbated by polyglutamine expansion. This baseline understanding is essential for distinguishing normal protein function from the toxic gain-of-function mechanism characteristic of pathogenic variants. ## Clinical Significance The Q27 variant represents a normal, non-pathogenic allele that serves as a critical reference point for clinical and research applications. Baseline data collection for this wildtype variant enables precise quantification of the relationship between polyglutamine tract length and disease parameters including penetrance, age of onset, and symptom severity. This reference is particularly valuable for understanding intermediate alleles and establishing diagnostic thresholds that distinguish normal variation from pathogenic expansion. Longitudinal biomarker studies comparing wildtype and expanded ATXN3 variants provide essential data for clinical trial design, allowing researchers to identify biomarkers that track disease progression while preserving sensitivity to therapeutic interventions. The establishment of normal ATXN3 function parameters is crucial for developing therapeutic strategies that selectively target mutant protein while maintaining wildtype protein activity necessary for normal cellular homeostasis. ## Therapeutic Landscape The identification of an aggregation hotspot at residues 148-152 in wildtype ATXN3 provides a targetable region for therapeutic development, though intervention strategies must carefully preserve normal protein function. Current therapeutic approaches for SCA3 focus on length-dependent strategies that distinguish between wildtype and expanded alleles, including antisense oligonucleotides and RNA interference targeting preferentially expanded transcripts. The wildtype protein's structural characteristics, now defined through AlphaFold modeling (5 available structures), offer templates for designing selective inhibitors. Understanding the normal phase separation behavior and stress response mechanisms of wildtype ataxin-3 informs the development of therapies that modulate protein homeostasis pathways without disrupting essential deubiquitinase functions. No specific peptide inhibitors have been reported targeting the wildtype variant, reflecting the therapeutic focus on pathogenic expansions rather than normal protein inhibition. ## Research Directions Critical knowledge gaps remain in understanding how subtle variations in polyglutamine length within the normal range (including Q27) affect protein stability, interaction networks, and cellular functions. Future research should investigate whether wildtype ATXN3 variants influence susceptibility to protein aggregation diseases through trans-acting effects or altered proteostasis capacity. The delineation of precise functional differences between wildtype variants and intermediate-length alleles (40-59 repeats) would clarify penetrance mechanisms and identify individuals at risk for late-onset or mild symptoms. Comprehensive characterization of wildtype ATXN3 interactions with VCP, BECN1, and other partners under various cellular stress conditions could reveal compensatory mechanisms that prevent aggregation. Additionally, exploring whether therapeutic strategies targeting expanded ATXN3 inadvertently affect wildtype protein function remains an essential consideration for ensuring treatment safety and preserving normal cellular proteostasis. --- ## Agent Findings ### Literature (1) - **2026-06-24:** These papers are highly relevant for understanding ATXN3 wildtype Q27 function in the context of SCA3 pathogenesis. They provide critical insights into the biophysical properties of normal versus expanded polyQ ATXN3 (phase separation, aggregation), cellular stress response mechanisms disrupted by mutation, genetic modifiers that influence disease phenotype, and longitudinal biomarkers for tracking disease progression. Understanding wildtype ATXN3 behavior is essential for developing targeted therapies and interpreting how normal-range CAG repeats (like Q27) differ mechanistically from pathogenic expansions. ### Clinical (1) - **2026-06-24:** The collection of first baseline data for the ATXN3 wildtype Q27 variant establishes a normal reference point, as Q27 (27 CAG repeats) falls within the non-pathogenic range for Machado-Joseph disease (pathogenic expansions typically begin at ≥60 repeats). This baseline is clinically significant for comparing against pathogenic expanded alleles to quantify the relationship between polyglutamine tract length and disease penetrance, age of onset, and symptom severity. These data enable researchers to distinguish normal ATXN3 function from the toxic gain-of-function mechanism associated with expanded repeats, which is essential for developing length-dependent therapeutic strategies. ### Structural (1) - **2026-06-24:** AlphaFold structure update: Baseline check: 5 structure(s) found ### Synthesis (1) - **2026-06-24:** Synthesis of 1 findings (peptides): The computational peptide design effort for ATXN3 wildtype Q27 (associated with Spinocerebellar atax... --- *Generated by [Clarity Protocol](https://clarityprotocol.io)* **Data Sources:** - Structure predictions: AlphaFold via ColabFold - Clinical variant data: ClinVar, gnomAD - Disease associations: Open Targets Platform - Research findings: AI agents (PubMed, clinical databases)